|[February 12, 2013]
McLaren Cancer Institute Names New Leader
FLINT, Mich. --(Business Wire)--
McLaren Health Care has selected Justin F. Klamerus, M.D., to guide
McLaren Cancer Institute as its interim president and medical director.
Klamerus will transition into the position, replacing Dr. Ray Demers,
who will retire March 31, 2013, after serving more than 10 years as
president and medical director.
"We're proud to welcome Dr. Klamerus to McLaren Cancer Institute during
this very exciting time," said Phil Incarnati, president and CEO of
McLaren Health Care. "His strategic leadership and clinical expertise
will add to the strong foundation already in place at McLaren Cancer
Institute and will help us launch new initiatives to treat cancer
patients, such as the McLaren Proton Therapy Center."
Dr. Klamerus is a medical oncologist who most recently served as
director of cancer services for McLaren Northern Michigan in Petoskey
and medical director for the Oncology & Infusion Therapy Center at
Otsego Memorial Hospital in Gaylord. Klamerus also has served as a
principal investigator for McLaren Cancer Institute. He will continue to
see patients in Northern Michigan.
"I look forward to building on the strengths of a network of talented
professionals serving cancer patients in our system," said Dr. Klamerus.
"McLaren Cancer Institute is poised to make a real difference. With the
construction of the new McLaren Proton Therapy Center, we will offer
enhanced radiation therapy services available nowhere else in Michigan.
McLaren's commitment to fighting cancer couldn't be more apparent."
As interim president and medical director, Dr. Klamerus will provide
leadership and direction to the medical and adminisrative staff. His
responsibilities also include establishing and maintaining quality care
standards and metrics, overseeing continued growth of the cancer
clinical trials program and ensuring exceptional patient care throughout
McLaren Cancer Institute.
Dr. Klamerus is a diplomate of the American Board of Internal Medicine
and is board certified in medical oncology and internal medicine. He is
a member of the American College of Physician Executives, and an
associate to both the American Society of Clinical Oncology and the
American College of Physicians. Dr. Klamerus has authored more than 10
publications or chapters and has been the principal researcher for more
than a dozen active clinical protocols.
He attended Michigan State University's College of Human Medicine and
completed his internship and residency at Ohio State University and a
fellowship in medical oncology at Johns Hopkins University. Dr. Klamerus
will complete a Master of Medical Management from H. John Heinz III
College at Carnegie Mellon University in February 2013.
About McLaren Cancer Institute
The McLaren Cancer Institute is a wholly owned subsidiary of the McLaren
Health Care Corporation. Its premise is to facilitate the integration of
evidence-based oncology research with state-of-the-art cancer treatment
and deliver newly discovered treatment options to physicians and
patients in communities throughout Michigan. By conducting important
research and connecting researchers with local providers, we enhance
existing knowledge of cancer and translate research findings to patient
care more quickly. The nonprofit system includes
cancer centers affiliated with community and regional hospitals of the
McLaren Health Care system, including Bay Region, Central Michigan,
Clarkston, Greater Lansing, Lapeer Region, Flint, Macomb, Northern
Michigan and Oakland, as well as affiliate partnerships with
Marquette General Health System and Memorial Cancer Center in Owosso.
About McLaren Health Care
With headquarters in Flint, Mich., McLaren Health Care is annually
recognized as one of the top integrated health networks in the nation.
McLaren is one of the largest health care providers in the state with a
system that reaches more than half of Michigan residents through more
than 200 locations, 17,400 employees and 11,000 network physicians.
McLaren Health Care had net revenues of $2.5 billion in 2012 and has
experienced double-digit growth each year since 1989. The nonprofit
system includes medical centers in Bay City, Flint, Lapeer, Lansing,
Mount Clemens, Mount Pleasant, Petoskey and Pontiac. Additional health
care services are provided at McLaren Clarkston; McLaren Bay Special
Care in Bay City; McLaren Orthopedic Hospital in Lansing; and McLaren
Proton Therapy Center in Flint (beginning in 2013). McLaren Health Care
also operates McLaren Medical Group, an employed physician network;
McLaren Homecare Group, an award-winning home health, hospice and
medical supplies provider; McLaren Health Plan, a licensed HMO offering
benefit plans for commercial businesses and Medicaid recipients; and
McLaren Cancer Institute, the largest cancer care network of its kind in
the state. For more information, visit mclaren.org.
[ Back To Technology News's Homepage ]